Cargando…
Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
The objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy. The case examined here is a 60-year-old white male diagnosed with...
Autores principales: | Randles, Heather H., Abraham, Nina, Schuh, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051901/ https://www.ncbi.nlm.nih.gov/pubmed/34007593 http://dx.doi.org/10.24926/iip.v10i4.2303 |
Ejemplares similares
-
Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial
por: Stäuble, Céline K., et al.
Publicado: (2021) -
Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019) -
Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
por: Schuh, Michael J.
Publicado: (2019) -
Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
por: Schuh, Michael J., et al.
Publicado: (2020) -
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019)